collaborative investor engagement · 2024
FAIRR Initiative
FAIRR convened investors to press seven of the largest publicly listed animal pharmaceutical companies for disclosure on how, and whether, they address antimicrobial resistance across their value chain from factory to farm, covering manufacturing, labelling, marketing and sales practices, and to press them to future-proof their antibiotic portfolios and invest in alternatives. Phase 2 was supported by 80 investors with US$17.4 trillion in combined assets.
What happened
Result: Phase 2 was supported by 80 investors representing US$17.4 trillion in combined assets, and FAIRR published its progress report From Farms to Forks: Antibiotic Stewardship in the Animal Pharmaceutical and Quick Service Restaurant Sectors in May 2024.
FAIRR went on to co-develop an investors' guide to antimicrobial resistance with the MSCI Sustainability Institute and IAAMR, setting out how investors can act on AMR.
Who is involved
- FAIRR Initiative filer
- Zoetis company
- Elanco Animal Health company
- Merck & Co. Animal Health company
- Dechra Pharmaceuticals company
- Phibro Animal Health company
- Vetoquinol SA company
- Virbac Group company